Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits

Hyperglycemia is an undisputed epidemiological risk factor for microvascular complications in both type 1 and type 2 diabetes, integral in their causal pathways. Importantly, interventions that reduce the hyperglycemic burden in patients with either type of diabetes reduce the risk of microvascular...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Pharm Policy Pract
Autors principals: McGuire, Darren K., Inzucchi, Silvio E., Johansen, Odd Erik, Rosenstock, Julio, George, Jyothis T., Marx, Nikolaus
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Commentary
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8048355/
https://ncbi.nlm.nih.gov/pubmed/33858511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40545-020-00295-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars